Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy.
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Selumetinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms SEL-I-METRY
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.
- 01 Aug 2016 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2016.
- 01 Aug 2016 Status changed from recruiting to not yet recruiting.